Digipath
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

(PRN) Bigger Capital and District 2 Capital Issue

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (11) | Next 10 | Previous | Next
tctrader38 Member Profile
 
Followed By 2
Posts 40
Boards Moderated 0
Alias Born 06/26/18
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/8/2019 6:04:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2018 4:18:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:17:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/28/2018 5:28:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 1:44:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2018 5:38:07 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/15/2018 3:15:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 4:49:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2018 4:24:26 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2018 4:52:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2018 5:23:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/28/2018 4:12:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2018 5:16:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2018 4:34:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2018 5:01:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2018 7:03:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2018 4:44:29 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/16/2018 5:06:32 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/16/2018 4:42:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2018 5:26:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2018 3:52:43 PM
Traders News Source Issues Research Reports on ANDI, FUSZ, RNVA and NWBO InvestorsHub NewsWire - 4/19/2018 8:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/17/2018 5:11:43 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 4/12/2018 5:26:20 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/9/2018 4:15:48 PM
tctrader38   Thursday, 11/15/18 08:31:26 AM
Re: None
Post # of 209723 
(PRN) Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L, a Second-Generation Autologous Dendritic Cell Va
________________________________________
Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L, a Second-Generation Autologous Dendritic Cell Va
2018-11-15 13:30:02.991 GMT

Link to White Paper

Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L,
a Second-Generation Autologous Dendritic Cell Vaccine

In-depth Analysis of Northwest Biotherapeutics' Cancer Vaccine by an Expert in
Cellular and Molecular Medicine Trained at the Johns Hopkins School of
Medicine and the Ludwig Center for Cancer Genetics and Therapeutics

DCVax-L Interim Efficacy and Safety are Impressive, Clinical Manufacturing is
a Surmountable Challenge, and the Regulatory Environment for GBM, a Deadly
Disease with Severe Unmet Need, is Favorable

Northwest Biotherapeutics May be a Severely Discounted Cancer Immunotherapy
Company

PR Newswire

HUNTINGTON, N.Y., Nov. 15, 2018

HUNTINGTON, N.Y., Nov. 15, 2018 /PRNewswire/ -- Bigger Capital Fund, LP and
District 2 Capital Fund LP, together with their affiliates (collectively, the
"Funds"), hedge funds that invest primarily in biotechnology companies,
announce that Carlo Rago, PhD, who has an extensive background in the
biotechnology industry, authored a white paper in support of DCVax-L, a
second-generation autologous dendritic cell vaccine, produced by Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"). The
white paper focuses on the potential value of the therapeutic platform the
Company has created. The paper considers, among other things, the benefits
dendritic cell vaccines are beginning to produce for cancer patients and their
role as an important tool for cancer immunotherapy strategies. The paper
reviews DCVax-L's phase III interim results in newly diagnosed glioblastoma
("GBM") patients and highlights what Dr. Rago believes is an underappreciated
detail that suggests the vaccine may be operating through the proposed
mechanism, dendritic cell activation of T cells against cancer-specific
antigens.

The white paper entitled: "A Second-Generation Dendritic Cell Cancer Vaccine
Preparing to Shine" is available at the following links:

http://biggercapital.squarespace.com/storage/value/NWBO%20-%20White%20Paper%20Rago_48081593.pdf

www.biggercapital.com

Based on Dr. Rago's assessment about the viability of DCVax-L, the Funds
believe the current trading price of the Company's securities is not
reflective of their value. As indicated below, the Funds and Dr. Rago own
securities of the Company. They may also engage in future transactions with
respect to securities of the Company, including both purchases and sales.

About Bigger Capital Fund, LP and District 2 Capital Fund LP: Bigger Capital
Fund, LP ("Bigger Capital") and District 2 Capital Fund LP ("District 2
Capital") are research intensive hedge funds that invest primarily in
Biotechnology. The Funds are affiliated entities. Bigger Capital commissioned
Dr. Rago to author the white paper.

Carlo Rago, PhD – currently serves as a Biotechnology consultant including to
the Funds. Dr. Rago received his PhD in Cellular and Molecular Medicine at The
Johns Hopkins University School of Medicine and conducted a post-doctoral
fellowship at the Johns Hopkins Ludwig Center for Cancer Genetics and
Therapeutics. He was the Chief Scientific Officer and Co-Founder of DMD
Therapeutics, Inc., a Co-Founder and the Scientific Director of the Duchenne
Alliance, Scientific Director of Ryan's Quest, and Founder and Chief Executive
Officer of OpenOnward.

Dr. Rago will be attending the Annual Meeting and Education Day of the Society
for Neuro-Oncology in New Orleans on November 15-18, 2018, and will be
available to answer questions about the white paper.

Disclosures
Carlo Rago, PhD owns Northwest Biotherapeutics Common Stock. In addition, Dr.
Rago serves as a Consultant to Bigger Capital and District 2 Capital. Dr.
Rago's compensation depends on the performance of the securities in the Funds'
portfolio. The Funds own Common Stock and Warrants of Northwest
Biotherapeutics.

This press release may contain forward-looking statements, including
statements as to anticipated or expected results, beliefs, opinions, and
future financial performance. The forward-looking statements are based on
current expectations and assumptions and involve risks and uncertainties that
may cause the Company's actual experience to differ materially from that
anticipated.

The views contained in this press release and the white paper referenced
herein represent the opinions of the Funds and Dr. Rago as of the date hereof
based solely on publicly available information and do not represent medical or
investment advice in any way. In addition, the efficacy and safety of DCVax-L
is only one element in valuing the securities of the Company. Investors and
other interested parties of the Company are encouraged to do their own
analysis of DCVax-L and the Company. Each of the Funds and Dr. Rago reserves
the right to change any of its or his opinions expressed herein or in the
white paper at any time and for any reason and expressly disclaims any
obligation to correct, update or revise the information contained herein or in
the white paper. The information contained in this press release and the white
paper may not contain all of the information required in order to evaluate the
value of the Company or its securities. Investors should seek independent
scientific or financial advice regarding the efficacy and safety of DCVax-L,
the suitability of investing in any securities or of following any investment
strategies; neither the Funds nor Dr. Rago is offering or providing such
services in connection with this press release or the white paper or otherwise
making a recommendation to buy or sell any of the Company's securities.

Contact
Bigger Capital at https://twitter.com/biggercapital

Carlo Rago, PhD at https://twitter.com/rago_carlo or
https://www.linkedin.com/in/carlo-rago-7695151/

Cision View original
content:http://www.prnewswire.com/news-releases/bigger-capital-and-district-2-capital-issue-white-paper-in-support-of-dcvax-l-a-second-generation-autologous-dendritic-cell-vaccine-300750945.html

SOURCE Bigger Capital Fund, LP

-0- Nov/15/2018 13:30 GMT


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (11) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist